Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Interim phase I data on Arrowhead's ARO-APOC3 and ARO-ANG3 show improvements in lipid parameters

Feb. 6, 2020

Saroglitazar approved in India as add on treatment for type 2 diabetes

Feb. 5, 2020

Follicum receives grant to study binding of FOL peptides to pancreatic cell receptors

Feb. 3, 2020

Phase I study of Rani's orally delivered octreotide meets primary and secondary endpoints

Jan. 31, 2020

Sanofi reports topline results with olipudase alfa in acid sphingomyelinase deficiency

Jan. 30, 2020

New phase II trial studies REGN-4461 for generalized lipodystrophy

Jan. 30, 2020

FDA approves Monoferric injection for the treatment of iron deficiency anemia

Jan. 30, 2020

Phase II study of AKCEA-ANGPTL3-LRx meets primary endpoint of significant triglyceride lowering

Jan. 29, 2020

Melanocortin MC2 receptor antagonists disclosed by Crinetics Pharmaceuticals

Jan. 29, 2020

Mutant TP53 affects fat metabolism

Jan. 29, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...